Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $206.67

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $206.67.

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup boosted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Chardan Capital restated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Several institutional investors have recently modified their holdings of KRYS. Segall Bryant & Hamill LLC grew its stake in shares of Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp grew its stake in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Braidwell LP grew its stake in shares of Krystal Biotech by 57.4% in the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock worth $30,707,000 after purchasing an additional 61,512 shares during the last quarter. Finally, Edgestream Partners L.P. bought a new stake in shares of Krystal Biotech in the third quarter worth $5,872,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 0.1 %

NASDAQ KRYS opened at $159.20 on Friday. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The company has a 50 day moving average of $167.60 and a 200-day moving average of $180.66. The company has a market cap of $4.58 billion, a price-to-earnings ratio of 89.94 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the business earned ($0.67) earnings per share. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. On average, equities research analysts forecast that Krystal Biotech will post 3.03 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).